Webinar Technology

Humanized mouse models in checkpoint inhibitor development

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Humanized mouse models in checkpoint inhibitor development

Recorded 23 August 2017


Humanized tumor xenograft mouse models are powerful experimental systems for studying in vivo interactions between human immune cells and human tumors. These models are generated by engrafting both human hematopoietic stem cells and human tumor tissue into immunodeficient mice, such as the NOD/SCID gamma (NSG) strain. In recent years, humanized tumor xenograft mouse models have been integrated into checkpoint inhibitor development programs at many pharmaceutical and biotechnology companies as an indispensable part of the drug development process. As these models have improved, they have been shown to support higher levels of human myeloid-derived cells and regulatory T cells, and have been used successfully in recent studies of anti-PD1 drugs in lung, breast, bladder, and melanoma. Join our experts to hear about the latest research developments utilizing these cutting-edge models.


During this webinar our panelists will:

• Explain the biology of human immune cells and human tumor cells/tissue in the humanized NSG environment

• Describe in vivo responses of human cell-line xenografts and human patient-derived tumor xenografts to checkpoint inhibitor treatments

• Discuss strategies for designing experiments to test combination therapy in vivo

• Answer your questions live during the broadcast!

This Webinar will last for approximately 60 minutes.

Speaker bios

Barbara Joyce-Shaikh, B.S.

Merck Research Laboratories
Palo Alto, CA

Ms. Joyce-Shaikh completed her B.S in molecular biology at San Jose State University. She has more than 20 years of biotech industry experience specializing in translational systems of immune function and immuno-oncology. Her work has contributed to several patents as well as peer-reviewed publications in several high-ranking international scientific journals, including Nature, Immunity, Nature Medicine, and the Journal of Experimental Medicine. She is currently a project lead in the Immuno-Oncology Discovery group at Merck Research Laboratories in Palo Alto, California (formerly the DNAX Research Institute). Her research utilizes syngeneic and humanized mouse tumor systems to model the tumor microenvironment, with the goal of discovering novel immunomodulatory agents and combinatorial treatments to fight drug-resistant cancers.

James Keck, Ph.D.

The Jackson Laboratory
Sacramento, CA

Dr. Keck’s expertise is in animal pharmacology, assay development, drug discovery, target identification, protein expression, and translational research. His work has encompassed several therapeutic areas including oncology, virology, and inflammatory and metabolic diseases. As his career progressed, Dr. Keck was part of a business development team, making presentations to potential corporate partners and interacting with collaborators in industrial and academic centers. He was also a member of a clinical team, coauthoring clinical investigator brochures, Food and Drug Administration (FDA) progress reports, and clinical protocols. Under his leadership, teams of scientists developed high-throughput assays in the areas of oncology, inflammatory and metabolic diseases, viral transcription, and gene function. In his current position at The Jackson Laboratory, he has overall responsibility for the ongoing operational development of the PDX resource, which generates, banks, and distributes patient-derived xenograft (PDX) mouse models of human cancers. The laboratory’s Oncology Preclinical Services team, which offers preclinical efficacy studies using PDX and other models, including humanized (hu)-NSG mice, is also under his direction.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here